Loading people...
John Josey is a Venture Partner at The Column Group based between Dallas, Texas, and the San Francisco Bay Area. Before joining the firm in 2020, he served as President and Chief Executive Officer of Peloton Therapeutics from 2013 to 2019, ultimately leading the company through its $2.2 billion acquisition by Merck. His earlier career spans over twenty-five years in drug discovery, including a thirteen-year tenure as Vice President of Discovery Chemistry at Array BioPharma and scientific roles at Amgen. He holds a doctorate in organic chemistry from the University of Texas at Austin, a master of business administration from the University of Colorado, and completed postdoctoral research at the California Institute of Technology. Today, Josey focuses his expertise on building and advising early-stage biotechnology ventures from scientific platforms, recently helping establish Atavistik Bio alongside Lux Capital.
John Josey is a distinguished Venture Partner at The Column Group, a leading life sciences venture capital firm renowned for its unique approach to company creation and investment in groundbreaking drug discovery. In his pivotal role, John Josey is instrumental in identifying, evaluating, and supporting early-stage biotechnology companies that are poised to revolutionize therapeutic development.
At The Column Group, the focus is on building innovative companies from the ground up, often partnering with world-class scientists to translate cutting-edge research into viable drug candidates. John Josey's contributions are central to this mission, leveraging his deep industry knowledge and strategic insights to guide these nascent ventures. His investment focus areas typically include novel therapeutic platforms, precision medicine, and drug candidates addressing high-impact diseases across various therapeutic categories. He is particularly interested in ventures that demonstrate strong scientific rigor, significant market potential, and the ability to deliver transformative patient outcomes.
While specific details of John Josey's career background are integral to his current success, it is understood that Venture Partners at The Column Group possess extensive experience in the pharmaceutical and biotechnology sectors. This often includes a strong foundation in scientific research and development, operational leadership within biotech companies, or prior experience in venture capital with a life sciences specialization. This background equips John Josey with the critical ability to assess complex scientific proposals, understand the intricacies of drug development pathways, and provide invaluable strategic guidance to portfolio companies.
John Josey's work extends beyond capital allocation; he actively engages with portfolio company leadership, offering mentorship, strategic planning, and access to a vast network of scientific and industry experts. This hands-on approach is vital for transforming innovative scientific ideas into successful enterprises capable of bringing new medicines to patients. His involvement helps de-risk early-stage investments and accelerate the development of potentially life-changing therapies.
Through his dedication and expertise as a Venture Partner at The Column Group, John Josey plays a significant role in fostering the next generation of biotechnology leaders and driving scientific innovation forward. His commitment ensures that promising discoveries receive the necessary support to evolve into impactful solutions for global health challenges.
John Josey is a Venture Partner at The Column Group, a prominent life sciences venture capital firm focused on early-stage biotechnology and drug discovery investments.
John Josey invests in early-stage biotechnology companies, novel drug discovery platforms, and therapeutic candidates that address significant unmet medical needs, primarily through his role at The Column Group.
John Josey works as a Venture Partner at The Column Group, a leading life sciences venture capital firm known for creating and investing in innovative drug discovery companies.
